H eart failure (HF) remains one of the largest health problems in the Western world that caused an estimated 37.6 million HF or HF-related hospitalizations in the United States between 2001 and 2009. 1 After an insult to the myocardium, cardiac output drops, which will lead to impairment of the systemic circulation and ultimately signs and symptoms of HF. Indeed, tissue and organ perfusion generally decreases in HF, despite the fact that local compensatory mechanisms are activated. To maintain sufficient perfusion of vital organs and peripheral tissues, vasoconstrictor mechanisms in the systemic arterial bed become active in response to stimulation of the sympathetic nervous and reninangiotensin system. 2 This has paved the way for the use of arterial vasodilators in HF because long-term systemic vasoconstriction leads to left ventricular hypertrophy and failure and ultimately refractory HF. As a consequence of left-sided HF, pulmonary congestion may occur. Previously, pulmonary congestion was considered mainly a marker of severity of left-sided HF, but there is increasing evidence that pulmonary congestion may also be actively contributing to the HF syndrome and impair prognosis. 3 Along with previous attempts to indirectly monitor signs related to pulmonary congestion in HF, 4 there is a (renewed) interest in more directly measuring pulmonary artery (PA) pressures in HF. Moreover, elevated PA pressures have been shown to strongly associate with an adverse prognosis and increased risk for hospitalization in patients with HF ( Figure) . 5 For this reason, the pulmonary circulation as a therapeutic target in HF has gained increasing interest in recent years.
In 2011, the results of the CHAMPION trial (CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients) were reported. 6 In the CHAMPION trial, 550 patients with moderate HF were randomized to management of their HF with either the wireless PA hemodynamic monitoring system (CardioMEMS, St. Jude Medical) or standard of care (control) treatment. For patients in the active treatment arm, clinicians used daily measurements of PA pressures to guide their HF management. The treatment goal was to lower PA pressures when elevated with neurohormonal, diuretic, or vasodilator drugs. 6 The control group continued to receive standard treatment, and changes in medication were based only on patients' signs and symptoms. 6 PA pressures decreased to a larger extent in the treatment group than in the control group (−156 versus 33 mm Hg•d, respectively; P=0.008), and this was associated with a 28% reduction in HF-related hospitalizations. This CHAMPION study thus provided promising data, and in the most recent 2016 European Society of Cardiology heart failure management guidelines, wireless PA pressure monitoring received a Class IIb-B recommendation to reduce recurrent HF hospitalizations. 7 Nevertheless, additional data, for example in other patients groups, were clearly welcome.
Measuring Pulmonary Artery Pressures in Heart Failure
A New Useful Diagnostic Tool?
In this issue of Circulation, Heywood et al 8 describe their experience with 2000 US patients from the general HF community who were implanted with the same wireless PA pressure monitoring system after this device received market approval in the United States. The study shows a significant reduction in PA pressures during a follow-up of 333±125 days. Comparing the present study population with the patients in the CHAMPION trial shows that patients in the present study were older and there was a higher proportion of patients with left ventricular ejection fraction (LVEF) ≥40%, whereas PA pressures at baseline were slightly but not significantly higher. During the 6 months of the study, the reduction in PA pressures was higher in these general-use patients compared with the patients in the CHAMPION trial (−434.0 versus −150.1 mm Hg•d, respectively). In the 1024 patients in the present study in whom LVEF was available at baseline, the decrease in PA pressure was the same in patients with HF with reduced LVEF and those with preserved LVEF (P=0.81), 8 The strengths of this study are clearly the large number of patients and the apparent good clinical use of this device in a large spectrum of patients with HF. Limitations of this study include the relatively sparse documentation of the patient population, the lack of safety data, and the fact that clinical end points (eg, hospitalizations and deaths) were not collected. Indeed, this study was a registry and not a randomized clinical trial in which an intervention was investigated.
Despite these limitations, the study by Heywood et al 8 provides important novel information about the diagnostic use of PA pressures in patients with HF, both patients with HF with reduced LVEF and those with preserved LVEF. For patients with HF with reduced LVEF, major progress in the last 20 to 25 years has been made in their management. Indeed, big steps forward have been achieved in the field of pharmacological treatment, but also in device therapy (in particular, cardioverter-defibrillator and cardiac resynchronization therapy), to improve their quality of life and to reduce mortality. 7 With regard to patients with HF with preserved LVEF, very little, if any, improvement has been achieved in recent years, despite the fact that patients with HF with preserved LVEF have a similarly poor prognosis as HF patients with a reduced LVEF. 9, 10 For this reason, the present findings of Heywood et al 8 may be particularly relevant for HF patients with preserved LVEF because they are in line with earlier similar findings from CHAMPION in this population. 11 Among patients with HF with preserved LVEF, ≈68% suffer from pulmonary hypertension, and the risk of mortality increases with 30% for every 5-mm Hg increase in PA pressure. 12 The finding that PA pressures can be significantly reduced in such patients by using the wireless monitor as a diagnostic tool to adjust individual medical treatment is therefore interesting because several randomized trials that aimed at reducing PA pressures with specialized drugs in HF with preserved LVEF were unsuccessful. 13, 14 When the wireless monitor is used, it would seem useful to have a clear algorithm to guide clinicians and HF-specialized nurses to act on the observed changes in PA pressure. From the CHAMPION trial, the exact diagnostic algorithm is unknown, but conventional loop and thiazide diuretics appeared to be mainly responsible for the important reduction in PA pressures and hospitalization rates in the intervention group: 64.9% of all medication changes in patients with HF with reduced LVEF and 73.5% of all changes in patients with HF with preserved LVEF. 11 It is known that a specific subgroup of HF patients with long-standing pulmonary venous hypertension may develop a precapillary component of pulmonary hypertension. Especially in HF patients with "disproportional" high PA pressures, suggesting the presence of additional precapillary pulmonary hypertension, information from actual PA pressures recorded by the wireless pressure monitor may help in the development of better therapies targeting the pulmonary vasculature. Clearly, further research in other well-defined HF cohorts with combined postcapillary and precapillary pulmonary hypertension is needed to test such therapeutic concepts.
In conclusion, continuous monitoring of PA pressures may be an important component of successful HF management in both patients with HF with reduced and those with preserved LVEF. Although there are still significant challenges and more data would be helpful before larger use of this technique can be expected, the present findings of Heywood et al provide important new and supportive data in this field.
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